Our Oncology R&D strategy
推动创新，探索新领域，改变癌症治疗结果

• Antibody drug conjugates (ADC): 这些靶向药物将化疗药物输送到具有单克隆抗体的癌细胞, 通过化学连接连接到细胞毒性药物. This highly targeted and cell-specific mechanism has the potential to reduce side effects for those being treated with the drug. ¹
• Radioconjugates: 这种方法将放射疗法传递给肿瘤细胞, enabling cancer cells to be destroyed in a more targeted manner than traditional external beam radiation, 为患者提供更有针对性的治疗.
• DNA damage response (DDR): DNA damage is a critical factor in 肿瘤进展和大多数癌症更依赖于这一过程. DDR抑制剂阻断癌细胞中DNA损伤反应途径的特定组分, 导致癌细胞死亡，同时保持健康细胞完整. ² 
• Tumour drivers and resistance: We are developing therapies that directly target specific mutations and block resistance mechanisms that cause cancer cells to proliferate, with the goal of extending survival by targeting biological pathways and combating cancer as it evolves.
• Epigenetics: Dysregulation of epigenetic processes 是否会引发疾病，是癌症的标志. 通过研究这些表观遗传缺陷是如何导致癌症的, 澳门葡京赌博游戏可以开发针对这些变化的治疗方法.^3,4
• Immuno-oncology (IO): We are developing next-generation IO therapies to empower the immune system to more effectively recognise and kill cancer cells and to overcome the immunosuppressive mechanisms that cancers frequently develop as they evolve. We are focusing on novel combinations of IO therapies and designing bispecific antibodies that simultaneously target different immune checkpoints on the same cell.
• Immune engagers: A growing area of interest are T-cell engagers 是什么 重新引导 免疫系统的 t细胞识别并杀死癌细胞, 从而增强病人自身的抗癌免疫反应.⁵
• Cell therapy: We are building a pipeline of next-generation cell therapies that are designed to overcome current barriers to the widespread adoption of cell therapies for both solid and haematological tumours, 比如可伸缩性和可访问性方面的挑战. With our acquisition of Neogene therapeutics, 澳门葡京赌博游戏正在扩展到t细胞受体疗法(TCR-T), 通过靶向细胞内靶点开启癌症生物学的新空间.⁶

真正的潜力在于癌症治疗的结合，以获得更深入、更持久的反应

澳门葡京赌博游戏相信，真正的潜力在于综合治疗, attacking cancer cells from multiple angles. The breadth and depth of our portfolio allows us to trial many of these combinations to achieve a more durable, deeper response as we strive towards our ambition of transforming cancer outcomes and increasing the chance of cures. 

We are working towards a future where conventional chemotherapy and radiotherapy are replaced with targeted combinations of ADCs, molecularly targeted therapies, and immunotherapies. 

For example, combining ADCs that directly kill cancer cells with immunotherapies that drive the patient’s own immune response and support the tissue microenvironment to eradicate the tumour, 是否有助于推动更强、更持久的患者反应. We are also exploring the potential for maximising DNA damage induced cancer cell death by combining ADCs with DDR inhibitors.
 

Treating cancer earlier and smarter
 

We are exploring the use of circulating tumour DNA (ctDNA), to detect cancer, 为患者选择正确的治疗方法，并确定治疗的有效性.

We have a collaboration with the company GRAIL to develop blood-based companion diagnostics for early-stage cancer. Through this collaboration, we will leverage GRAIL’s multi-cancer early detection test to recruit patients onto clinical trials for the investigation of our cancer treatments in early cancer. The test not only includes the potential to detect cancers with limited screening options at present but also importantly tells you which tissues they come from.⁷
 

Leading with transformational technologies
 

Data and AI

With the right data at our fingertips, 澳门葡京赌博游戏可以改变癌症药物的发现和开发，更快地为患者提供新的治疗方法. Data and AI are embedded across all of our R&D activities, 从新型抗癌药物新靶点的鉴定, predicting which molecules to make, better predicting clinical success, informing, and speeding up clinical trial recruitment. 数据和人工智能使澳门葡京赌博游戏能够利用新技术, automate processes and push the boundaries of science to accelerate innovation and the delivery of life-changing medicines.

Computational pathology

Computational pathology is the integration of machine learning and digital imaging with traditional pathology techniques as next generation diagnostics. Advances in data science and computing now allow us to integrate data from immunohistochemically stained cancer tissue images with genomic, radiological, clinical, and other data, 应用深度学习算法获得新的见解. 

定量连续评分(QCS)是澳门葡京赌博游戏的新发明, fully automated computational pathology solution that not only looks for the presence or absence of a biomarker but also quantifies the intensity of staining and its location in sub-cellular compartments. Right now, 澳门葡京赌博游戏在临床试验组合中率先使用QCS, 未来的目标是获得监管机构的批准，成为一流的人工智能驱动诊断技术.

Digital health

The digital capabilities we are embedding across our R&D对于创建人与数据之间的无缝连接至关重要. Our ambition is to reimagine healthcare – transforming patients’ healthcare journeys to improve earlier diagnosis, 更精确的治疗和主动的数字监测，以获得更好的结果, powered by digital, longitudinal data and AI, through the recent launch of Evinova, 澳门葡京赌博游戏的全球健康技术业务离这个目标更近了.

We are continuing to research, create and deliver digital health solutions, via Evinova, that are science-based, evidence-led, and human experience-driven. 精心设计，使每个人都能共同取得更好的健康成果.

The future of oncology R&D

澳门葡京赌博游戏相信，正是所有这些因素的结合，为澳门葡京赌博游戏未来的成功奠定了基础. By combining these innovations, 澳门葡京赌博游戏希望能改变癌症患者的预后和生存率.